ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,110 | -99.3% | 547 | -98.6% | 0.00% | -100.0% |
| Q2 2023 | $860,922 | -57.8% | 40,230 | -20.2% | 0.00% | 0.0% |
| Q1 2023 | $2,038,985 | -9.7% | 50,420 | +3.8% | 0.00% | -50.0% |
| Q4 2022 | $2,259,012 | -38.0% | 48,560 | -30.8% | 0.00% | -33.3% |
| Q3 2022 | $3,641,000 | +17.1% | 70,194 | +6.8% | 0.00% | +50.0% |
| Q2 2022 | $3,108,000 | +53.2% | 65,750 | +130.7% | 0.00% | +100.0% |
| Q1 2022 | $2,029,000 | -49.1% | 28,501 | -46.5% | 0.00% | -50.0% |
| Q4 2021 | $3,986,000 | +163.6% | 53,298 | +100.3% | 0.00% | +100.0% |
| Q3 2021 | $1,512,000 | -28.5% | 26,607 | -44.6% | 0.00% | 0.0% |
| Q2 2021 | $2,115,000 | -31.0% | 48,048 | -22.6% | 0.00% | -50.0% |
| Q1 2021 | $3,063,000 | +41.2% | 62,088 | +20.5% | 0.00% | +100.0% |
| Q4 2020 | $2,169,000 | -6.9% | 51,537 | +1.3% | 0.00% | -50.0% |
| Q3 2020 | $2,329,000 | +114.9% | 50,868 | +135.6% | 0.00% | +100.0% |
| Q2 2020 | $1,084,000 | +25.8% | 21,588 | +28.7% | 0.00% | 0.0% |
| Q1 2020 | $862,000 | -54.4% | 16,769 | -45.2% | 0.00% | 0.0% |
| Q4 2019 | $1,891,000 | -18.4% | 30,611 | -20.6% | 0.00% | -50.0% |
| Q3 2019 | $2,317,000 | -2.0% | 38,565 | +37.6% | 0.00% | 0.0% |
| Q2 2019 | $2,365,000 | +89.7% | 28,020 | +114.5% | 0.00% | +100.0% |
| Q1 2019 | $1,247,000 | -74.7% | 13,061 | -81.2% | 0.00% | -80.0% |
| Q4 2018 | $4,922,000 | +708.2% | 69,495 | +875.0% | 0.01% | +400.0% |
| Q3 2018 | $609,000 | +3283.3% | 7,128 | +4411.4% | 0.00% | – |
| Q2 2018 | $18,000 | -98.9% | 158 | -99.2% | 0.00% | -100.0% |
| Q1 2018 | $1,588,000 | +18.3% | 19,627 | -14.2% | 0.00% | 0.0% |
| Q4 2017 | $1,342,000 | +17.2% | 22,873 | -6.6% | 0.00% | 0.0% |
| Q3 2017 | $1,145,000 | +4.3% | 24,482 | -19.8% | 0.00% | 0.0% |
| Q2 2017 | $1,098,000 | +37.2% | 30,515 | +17.4% | 0.00% | 0.0% |
| Q1 2017 | $800,000 | -52.7% | 25,994 | -48.5% | 0.00% | -50.0% |
| Q4 2016 | $1,691,000 | +260.6% | 50,454 | +186.2% | 0.00% | – |
| Q3 2016 | $469,000 | +154.9% | 17,632 | +110.3% | 0.00% | – |
| Q2 2016 | $184,000 | -52.9% | 8,384 | -37.0% | 0.00% | – |
| Q1 2016 | $391,000 | +325.0% | 13,317 | +381.6% | 0.00% | – |
| Q4 2015 | $92,000 | -73.6% | 2,765 | -71.3% | 0.00% | – |
| Q3 2015 | $348,000 | +6.7% | 9,619 | +32.6% | 0.00% | – |
| Q2 2015 | $326,000 | +50.2% | 7,252 | +2.5% | 0.00% | – |
| Q1 2015 | $217,000 | -39.0% | 7,074 | +1.2% | 0.00% | – |
| Q4 2014 | $356,000 | +559.3% | 6,987 | +408.9% | 0.00% | – |
| Q3 2014 | $54,000 | +38.5% | 1,373 | +51.0% | 0.00% | – |
| Q2 2014 | $39,000 | +69.6% | 909 | +52.3% | 0.00% | – |
| Q1 2014 | $23,000 | -37.8% | 597 | -55.5% | 0.00% | – |
| Q4 2013 | $37,000 | – | 1,341 | +22250.0% | 0.00% | – |
| Q3 2013 | $0 | – | 6 | +20.0% | 0.00% | – |
| Q2 2013 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |